Autoimmune depigmentation following sensitization to melanoma antigens.
Generating an antitumor immune response can be thought of as eliciting an immune response to cells derived from self-tissue. As such, tumor immunity may result in autoimmunity. Melanoma patients undergoing immunotherapy often develop a form of autoimmune depigmentation referred to as vitiligo, in which T cells with antigenic specificity for pigmentation antigens destroy normal melanocytes. The models described in this chapter can be used to study immunity to melanoma antigens. These models employ a well-characterized pigmentation antigen relevant to melanoma and a common transplantable murine melanoma cell line. As more sophisticated approaches to cancer therapy are developed, models such as these may be key in understanding how immunity to self-antigens can be manipulated to elicit tumor immunity.
Hurwitz
Arthur A
AA
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.
Ji
Qingyong
Q
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001324:Autoantigens; D015551:Autoimmunity; D019496:Cancer Vaccines / Q000008:administration & dosage; D045744:Cell Line, Tumor; D006801:Humans; D017496:Hypopigmentation / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D016056:Immunodominant Epitopes / Q000008:administration & dosage; D019746:Intramolecular Oxidoreductases / Q000008:administration & dosage / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D051379:Mice; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology
D000951:Antigens, Neoplasm; D001324:Autoantigens; D019496:Cancer Vaccines; D016056:Immunodominant Epitopes; D010446:Peptide Fragments; D019746:Intramolecular Oxidoreductases; C042501:dopachrome isomerase